JC-171 is a selective NLRP3 inflammasome inhibitor used to block NLRP3 inflammasome activation and IL-1β production in primary macrophages; it is also used to delay progression and reduce the severity of experimental autoimmune encephalomyelitis (EAE) in mice by suppressing MOG35–55-specific Th17 cell responses.